Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.11. | CAMP4 Analyst Highlights Rare Disease Platform Potential | 2 | Benzinga.com | ||
05.11. | Camp4 gains after earning bullish views on Street | 1 | Seeking Alpha | ||
05.11. | William Blair upbeat on CAMP4 shares with Outperform rating | 3 | Investing.com | ||
05.11. | Leerink sets stock target for CAMP4, cites broad UCD treatment potential | 1 | Investing.com | ||
05.11. | Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology | 1 | Investing.com | ||
CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.11. | Piper Sandler optimistisch für CAMP4-Aktie, verweist auf Potenzial in bahnbrechender RNA-Technologie | 1 | Investing.com Deutsch | ||
05.11. | JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech | 4 | Investing.com | ||
16.10. | Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
15.10. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
11.10. | CAMP4 stock edges up 2% following $75M IPO | 5 | Seeking Alpha | ||
11.10. | RNA biotech CAMP4 Therapeutics prices IPO below the range at $11; adds shares to keep deal size at $75 million | 2 | Renaissance Capital | ||
11.10. | CAMP4 Therapeutics prices $75MIPO at $11 per share | 1 | Seeking Alpha | ||
11.10. | CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh | 2 | Investing.com | ||
11.10. | Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4 | 1 | FierceBiotech | ||
11.10. | CAMP4 Therapeutics: CAMP4 Announces Pricing of Initial Public Offering | 107 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting... ► Artikel lesen | |
08.10. | Upstream Bio, CeriBell, CAMP4 set terms for proposed IPOs | 1 | Seeking Alpha | ||
08.10. | Camp4 Therapeutics Corp - 8-A12B, Registration of securities | 1 | SEC Filings | ||
07.10. | CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans | 3 | FierceBiotech | ||
07.10. | Genetic disease biotech CAMP4 Therapeutics sets terms for $75 million IPO | 1 | Renaissance Capital | ||
07.10. | CAMP4 Therapeutics Announces 5M Share IPO at $14-$16/sh | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,175 | +3,44 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
EVOTEC | 10,060 | +1,56 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
BIONTECH | 98,35 | +0,77 % | Die meistgehandelten Produkte: BioNTech verstärkt sich mit Übernahme! | ||
GALAPAGOS NV | 23,960 | -0,33 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,725 | -5,22 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
GUBRA | 81,40 | -0,25 % | AKTIONÄR-Depotwert Gubra: Die Katze ist aus dem Sack! | Am Mittwoch nach Börsenschluss in Kopenhagen hat der Wirkstoffforscher Gubra erste Phase-1-Daten zu seinem Adipositas-Hoffnungsträger GUBamy vorgelegt. Diese sind äußerst vielversprechend und sollten... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 43,390 | -0,62 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
TELIX PHARMACEUTICALS | 13,595 | -4,33 % | Eckert & Ziegler: Top-Deal mit Telix Pharma - die Details! | Der Radiopharma-Markt ist und bleibt mächtig in Bewegung. Das unterfüttert ein neuer Kooperations- und Lizenzvertrag, den der deutsche Player Eckert & Ziegler mit dem australischen Radiopharma-Überflieger... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
UPSTREAM BIO | 18,010 | 0,00 % | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen | |
HUMACYTE | 4,430 | +0,45 % | Humacyte, Inc: Humacyte Clinical Results Highlighting Benefit of the ATEV in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery | ||
AMGEN | 274,20 | +0,37 % | Dividendenbekanntmachungen (18.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0569 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0,19 CAD 0,128 EUR ALLISON TRANSMISSION... ► Artikel lesen | |
4D MOLECULAR THERAPEUTICS | 8,000 | -4,88 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
PYXIS ONCOLOGY | 2,055 | -46,20 % | Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data | - PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line... ► Artikel lesen |